Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy

To evaluate costs of panretinal photocoagulation (PRP) vs. intravitreal ranibizumab (IVR) for proliferative diabetic retinopathy (PDR).

http://www.aaojournal.org/article/S0161-6420(16)30404-3/fulltext?rss=yes

Source: Ophthalmology - July 13, 2016 Category: Opthalmology Authors: James Lin, Jonathan S. Chang, William E. Smiddy Source Type: research

More News: Diabetes | Endocrinology | Lucentis | Opthalmology | Ranibizumab Injection